 Meredith Clement
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Exposure Prophylaxis | 19 | 2026 | 269 | 8.240 |
Why?
| | HIV Infections | 34 | 2026 | 3195 | 5.150 |
Why?
| | Anti-HIV Agents | 15 | 2026 | 912 | 3.500 |
Why?
| | Syphilis | 6 | 2017 | 38 | 2.650 |
Why?
| | Sexually Transmitted Diseases | 4 | 2023 | 168 | 2.480 |
Why?
| | Sexual and Gender Minorities | 6 | 2025 | 262 | 2.250 |
Why?
| | Homosexuality, Male | 9 | 2025 | 231 | 1.880 |
Why?
| | Sexual Health | 2 | 2024 | 68 | 1.350 |
Why?
| | Treponema pallidum | 2 | 2017 | 10 | 0.970 |
Why?
| | Hepatitis C | 3 | 2018 | 256 | 0.940 |
Why?
| | Penicillin G Benzathine | 2 | 2015 | 3 | 0.880 |
Why?
| | Louisiana | 4 | 2026 | 31 | 0.870 |
Why?
| | New Orleans | 4 | 2026 | 19 | 0.860 |
Why?
| | Obstetrics | 1 | 2026 | 177 | 0.830 |
Why?
| | Focus Groups | 2 | 2025 | 572 | 0.830 |
Why?
| | Gynecology | 1 | 2026 | 181 | 0.820 |
Why?
| | Injections, Intramuscular | 3 | 2021 | 146 | 0.730 |
Why?
| | Pyridones | 3 | 2023 | 209 | 0.720 |
Why?
| | Electronic Health Records | 3 | 2025 | 1202 | 0.680 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 2023 | 237 | 0.660 |
Why?
| | HIV-1 | 6 | 2026 | 908 | 0.650 |
Why?
| | Male | 37 | 2026 | 73003 | 0.610 |
Why?
| | Asymptomatic Infections | 2 | 2018 | 37 | 0.600 |
Why?
| | Continuity of Patient Care | 2 | 2019 | 297 | 0.600 |
Why?
| | Disease Eradication | 1 | 2018 | 7 | 0.550 |
Why?
| | Syphilis Serodiagnosis | 1 | 2017 | 5 | 0.540 |
Why?
| | Public-Private Sector Partnerships | 1 | 2018 | 44 | 0.530 |
Why?
| | Community Networks | 1 | 2018 | 57 | 0.510 |
Why?
| | Coinfection | 1 | 2018 | 143 | 0.490 |
Why?
| | Referral and Consultation | 2 | 2021 | 868 | 0.480 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 134 | 0.480 |
Why?
| | North Carolina | 4 | 2021 | 130 | 0.470 |
Why?
| | Humans | 44 | 2026 | 145763 | 0.470 |
Why?
| | Anti-Bacterial Agents | 3 | 2017 | 1925 | 0.460 |
Why?
| | Coronary Artery Bypass | 1 | 2018 | 268 | 0.460 |
Why?
| | Internship and Residency | 1 | 2026 | 1269 | 0.450 |
Why?
| | Hepatitis, Viral, Human | 1 | 2015 | 21 | 0.450 |
Why?
| | HIV | 3 | 2023 | 251 | 0.440 |
Why?
| | Universities | 1 | 2018 | 445 | 0.440 |
Why?
| | Physicians, Primary Care | 1 | 2017 | 208 | 0.430 |
Why?
| | Acute Coronary Syndrome | 1 | 2018 | 297 | 0.420 |
Why?
| | Public Health | 1 | 2019 | 574 | 0.410 |
Why?
| | Cardiac Catheterization | 1 | 2018 | 559 | 0.410 |
Why?
| | Antigens, Bacterial | 1 | 2014 | 126 | 0.400 |
Why?
| | Female | 29 | 2026 | 79035 | 0.400 |
Why?
| | Adult | 21 | 2026 | 40872 | 0.380 |
Why?
| | Sexual Behavior | 3 | 2022 | 495 | 0.380 |
Why?
| | Algorithms | 2 | 2018 | 1850 | 0.380 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2018 | 549 | 0.360 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 444 | 0.350 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1372 | 0.330 |
Why?
| | Cardiovascular Diseases | 3 | 2019 | 2191 | 0.320 |
Why?
| | Middle Aged | 17 | 2025 | 36302 | 0.300 |
Why?
| | United States | 9 | 2023 | 16123 | 0.280 |
Why?
| | Tenofovir | 4 | 2024 | 301 | 0.270 |
Why?
| | Veterans | 2 | 2017 | 1642 | 0.270 |
Why?
| | Medication Adherence | 3 | 2021 | 540 | 0.250 |
Why?
| | Diketopiperazines | 3 | 2023 | 23 | 0.250 |
Why?
| | Primary Health Care | 1 | 2017 | 1737 | 0.250 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2024 | 992 | 0.250 |
Why?
| | Health Services Accessibility | 2 | 2026 | 1101 | 0.240 |
Why?
| | Transgender Persons | 3 | 2024 | 210 | 0.230 |
Why?
| | Viremia | 1 | 2026 | 160 | 0.220 |
Why?
| | CD4 Lymphocyte Count | 2 | 2023 | 280 | 0.220 |
Why?
| | Drug Prescriptions | 2 | 2017 | 288 | 0.210 |
Why?
| | Retrospective Studies | 10 | 2023 | 17325 | 0.210 |
Why?
| | Antiviral Agents | 2 | 2021 | 769 | 0.200 |
Why?
| | Heart Ventricles | 2 | 2019 | 756 | 0.200 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 2000 | 0.190 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2024 | 1420 | 0.180 |
Why?
| | Trust | 1 | 2024 | 158 | 0.180 |
Why?
| | Hydroxychloroquine | 1 | 2022 | 65 | 0.180 |
Why?
| | Interviews as Topic | 1 | 2025 | 916 | 0.170 |
Why?
| | Sex Work | 1 | 2021 | 23 | 0.170 |
Why?
| | Aged | 10 | 2024 | 26215 | 0.170 |
Why?
| | Incidence | 3 | 2024 | 2933 | 0.160 |
Why?
| | Information Seeking Behavior | 1 | 2021 | 40 | 0.160 |
Why?
| | HIV Integrase Inhibitors | 1 | 2021 | 79 | 0.160 |
Why?
| | Condoms | 1 | 2021 | 102 | 0.160 |
Why?
| | Interleukin-6 | 1 | 2024 | 779 | 0.160 |
Why?
| | RNA, Viral | 2 | 2026 | 692 | 0.150 |
Why?
| | Clinical Alarms | 1 | 2019 | 11 | 0.140 |
Why?
| | Clinical Deterioration | 1 | 2019 | 10 | 0.140 |
Why?
| | Mass Screening | 2 | 2017 | 1361 | 0.140 |
Why?
| | Patient Acuity | 1 | 2019 | 48 | 0.140 |
Why?
| | Echocardiography | 2 | 2019 | 648 | 0.140 |
Why?
| | Qualitative Research | 1 | 2026 | 1683 | 0.140 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 340 | 0.140 |
Why?
| | Drug Interactions | 1 | 2020 | 405 | 0.140 |
Why?
| | Macrophages | 1 | 2026 | 1507 | 0.140 |
Why?
| | Cohort Studies | 3 | 2019 | 6032 | 0.140 |
Why?
| | Double-Blind Method | 4 | 2024 | 2064 | 0.130 |
Why?
| | Emtricitabine | 3 | 2024 | 210 | 0.130 |
Why?
| | Myocardial Contraction | 1 | 2019 | 293 | 0.130 |
Why?
| | Likelihood Functions | 1 | 2018 | 138 | 0.130 |
Why?
| | Valine | 1 | 2018 | 83 | 0.130 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2018 | 124 | 0.130 |
Why?
| | Chemoprevention | 1 | 2018 | 92 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2019 | 274 | 0.130 |
Why?
| | Immunoenzyme Techniques | 1 | 2017 | 200 | 0.130 |
Why?
| | Glutamine | 1 | 2018 | 109 | 0.130 |
Why?
| | Disease Transmission, Infectious | 1 | 2018 | 69 | 0.130 |
Why?
| | Carnitine | 1 | 2018 | 91 | 0.130 |
Why?
| | Pharmacogenetics | 1 | 2018 | 175 | 0.130 |
Why?
| | Antibodies, Bacterial | 1 | 2017 | 147 | 0.120 |
Why?
| | Machine Learning | 1 | 2023 | 587 | 0.120 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 883 | 0.120 |
Why?
| | Hepacivirus | 1 | 2018 | 242 | 0.120 |
Why?
| | Hepatitis C, Chronic | 1 | 2018 | 153 | 0.120 |
Why?
| | Stroke Volume | 1 | 2019 | 655 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 280 | 0.110 |
Why?
| | Ambulatory Care Facilities | 1 | 2018 | 269 | 0.110 |
Why?
| | Brain Death | 1 | 2015 | 60 | 0.110 |
Why?
| | Reagins | 1 | 2014 | 2 | 0.110 |
Why?
| | Dysuria | 1 | 2014 | 3 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2018 | 394 | 0.110 |
Why?
| | Exanthema | 1 | 2015 | 86 | 0.110 |
Why?
| | Serologic Tests | 1 | 2014 | 54 | 0.110 |
Why?
| | American Heart Association | 1 | 2016 | 358 | 0.100 |
Why?
| | Metabolome | 1 | 2018 | 391 | 0.100 |
Why?
| | Immunoassay | 1 | 2014 | 109 | 0.100 |
Why?
| | Cholesterol | 1 | 2016 | 408 | 0.100 |
Why?
| | Fever | 1 | 2015 | 319 | 0.100 |
Why?
| | Patient Selection | 1 | 2018 | 739 | 0.100 |
Why?
| | Risk | 1 | 2016 | 923 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 2017 | 892 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1711 | 0.100 |
Why?
| | Intention to Treat Analysis | 2 | 2024 | 79 | 0.100 |
Why?
| | Health Policy | 1 | 2015 | 400 | 0.090 |
Why?
| | Aspirin | 1 | 2015 | 406 | 0.090 |
Why?
| | Pregnancy | 2 | 2015 | 7215 | 0.090 |
Why?
| | Societies, Medical | 1 | 2016 | 900 | 0.090 |
Why?
| | Proteomics | 1 | 2018 | 1188 | 0.090 |
Why?
| | United States Department of Veterans Affairs | 1 | 2016 | 779 | 0.080 |
Why?
| | Pneumonia | 1 | 2017 | 636 | 0.080 |
Why?
| | Drug Administration Schedule | 2 | 2024 | 782 | 0.080 |
Why?
| | Administration, Oral | 2 | 2024 | 867 | 0.080 |
Why?
| | Clinical Competence | 1 | 2017 | 1247 | 0.070 |
Why?
| | Coronary Artery Disease | 1 | 2015 | 750 | 0.070 |
Why?
| | Decision Making | 1 | 2015 | 982 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1582 | 0.070 |
Why?
| | Hospitalization | 1 | 2018 | 2460 | 0.060 |
Why?
| | Risk Factors | 2 | 2018 | 10917 | 0.060 |
Why?
| | Spain | 1 | 2026 | 50 | 0.060 |
Why?
| | Drug Resistance, Viral | 1 | 2026 | 126 | 0.060 |
Why?
| | Injection Site Reaction | 1 | 2024 | 4 | 0.050 |
Why?
| | Europe | 1 | 2026 | 421 | 0.050 |
Why?
| | Severity of Illness Index | 2 | 2024 | 2933 | 0.050 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 6085 | 0.050 |
Why?
| | Acetamides | 1 | 2024 | 41 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2024 | 170 | 0.050 |
Why?
| | Indazoles | 1 | 2024 | 85 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2024 | 11793 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 396 | 0.050 |
Why?
| | Virus Replication | 1 | 2026 | 521 | 0.050 |
Why?
| | Chloroquine | 1 | 2022 | 54 | 0.050 |
Why?
| | Drugs, Generic | 1 | 2022 | 28 | 0.040 |
Why?
| | Prevalence | 2 | 2019 | 2874 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 14251 | 0.040 |
Why?
| | Assisted Living Facilities | 1 | 2021 | 20 | 0.040 |
Why?
| | Immunization, Passive | 1 | 2021 | 90 | 0.040 |
Why?
| | Drug Approval | 1 | 2021 | 93 | 0.040 |
Why?
| | Drug Resistance | 1 | 2021 | 145 | 0.040 |
Why?
| | Delayed-Action Preparations | 1 | 2021 | 189 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 428 | 0.040 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2026 | 1146 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 152 | 0.040 |
Why?
| | Adolescent | 3 | 2024 | 22573 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5428 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2026 | 736 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2022 | 644 | 0.040 |
Why?
| | Hospitals, Community | 1 | 2019 | 67 | 0.030 |
Why?
| | Diastole | 1 | 2018 | 146 | 0.030 |
Why?
| | Ribavirin | 1 | 2018 | 81 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2019 | 251 | 0.030 |
Why?
| | Interferons | 1 | 2018 | 186 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2024 | 1505 | 0.030 |
Why?
| | Interleukins | 1 | 2018 | 248 | 0.030 |
Why?
| | Nursing Staff, Hospital | 1 | 2019 | 143 | 0.030 |
Why?
| | Biomarkers | 2 | 2018 | 4302 | 0.030 |
Why?
| | Patient Transfer | 1 | 2019 | 211 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2015 | 54 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2019 | 544 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2018 | 615 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2019 | 554 | 0.030 |
Why?
| | Kenya | 1 | 2015 | 129 | 0.030 |
Why?
| | Health Personnel | 1 | 2021 | 757 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2019 | 1038 | 0.030 |
Why?
| | Risk Reduction Behavior | 1 | 2015 | 217 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2015 | 268 | 0.020 |
Why?
| | Genotype | 1 | 2018 | 1857 | 0.020 |
Why?
| | Comorbidity | 1 | 2018 | 1662 | 0.020 |
Why?
| | Odds Ratio | 1 | 2015 | 1083 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2019 | 924 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1197 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3170 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8346 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3634 | 0.020 |
Why?
| | Child | 1 | 2022 | 22739 | 0.010 |
Why?
|
|
Clement's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|